

FIGURE 1

Study Design

Group	Number of animals		Animal number		Treatment	Dose level		Concentration	Dose volume
	Male	Female	Male	Female		mg/kg	mg/mL		
1	1	1	1101	2102	Vehicle	0	0	0	10
2	1	1	1203	2204	sBCMA V3	0.1	0.01	0.01	10
3	1	1	1305	2306	sBCMA V3	1	0.1	0.1	10
4	1	1	1407	2408	sBCMA V3	10	1	1	10
5	1	1	1509	2510	sBCMA V3	100	10	10	10

All dose levels/concentrations in the table are nominal.

Bodyweight Recorded:
Pre-dose: Days -14, -6
After dose: Days 1, 2, 7, 14, 21, 28, 35 and 42.
Blood Sample Collected:
Pre-dose: Days -13, -6, 1
After dose: Days 2, 7, 14, 42

FIGURE 2
Male Cynomolgous Monkey Immune Cells Counts




FIGURE 2 - continued




FIGURE 3
Female Cynomolgous Monkey Immune Cells Counts




FIGURE 3 - continued




FIGURE 4




FIGURE 5




FIGURE 6

Changes of Immunoglobulin in the Females at 1 to 100 mg/kg

Parameters	Animal Number	Dose Level (mg/kg)	Day -6	Day 2	Day 7	Day 14	Day 42
IgA (g/L)	2306	1	1.33	/	-20%	-35%	/
	2408	10	0.9	/	-30%	-50%	-61%
	2510	100	0.98	/	-27%	-52%	-87%
IgG (g/L)	2408	10	9.12	/	/	-22%	/
	2510	100	12.24	/	/	-25%	-37%
IgM (g/L)	2306	1	1.49	/	-24%	-40%	/
	2408	10	0.96	/	-32%	-43%	-51%
	2510	100	0.93	/	-20%	-42%	-74%

Formula: (Parameter Day n - Parameter Day -6)/ Parameter Day -6 × 100%. /: No abnormality.

FIGURE 7

Changes of Immunoglobulin in the Males at 1 to 100 mg/kg							
Parameters	Animal Number	Dose Level (mg/kg)	Day -6	Day 2	Day 7	Day 14	Day 42
IgA (g/L)	1305	1	1	/	-19%	-44%	/
	1407	10	0.84	/	-18%	-31%	/
	1509	100	0.95	-20%	-37%	-54%	-75%
IgG (g/L)	1509	100	16.38	/	-34%	-44%	-56%
	1305	1	1.83	/	-24%	-38%	/
IgM (g/L)	1407	10	0.85	/	/	-25%	-29%
	1509	100	2.75	-38%	-56%	-70%	-82%

Formula: (Parameter Day n - Parameter Day -6)/ Parameter Day -6 × 100%. /: No abnormality.

FIGURE 8

Male Hematology Panel I

Vehicle Control	Day(s) Relative to Start Date	RBC	HGB	HCT	MCV	MCH	MCHC	RDW	RET
		(10^12/L)	(g/L)	(%)	(fL)	(pg)	(g/L)	(%)	(10^9/L)
1101	-13	6.21	139	49.4	79.6	22.4	281	13.3	192.0
	-6	5.89	133	47.4	80.6	22.6	280	13.1	121.0
	1	5.47	124	41.7	76.3	22.7	298	13.3	154.9
	2	5.29	119	43.7	82.5	22.5	273	13.4	198.3
	7	4.99	112	38.9	77.9	22.4	287	13.6	235.8
	14	5.42	124	40.5	74.6	22.8	305	13.3	169.3
42	5.81	129	42.6	73.4	22.3	303	13.4	109.6	

AB001 0.1 mg/kg	Day(s) Relative to Start Date	RBC	HGB	HCT	MCV	MCH	MCHC	RDW	RET
		(10^12/L)	(g/L)	(%)	(fL)	(pg)	(g/L)	(%)	(10^9/L)
1203	-13	5.61	126	43.5	77.6	22.4	289	13.5	209.8
	-6	6.23	140	47.9	76.8	22.5	293	12.9	140.6
	1	5.61	126	42.6	75.9	22.5	297	12.7	136.3
	2	5.12	114	39.0	76.2	22.3	292	12.9	157.0
	7	5.18	116	38.6	74.6	22.4	301	13.1	236.5
	14	5.55	122	40.2	72.4	22.0	304	12.9	178.4
42	6.14	139	44.4	72.3	22.6	313	12.1	89.2	

FIGURE 8 - continued

AB001 1 mg/kg	Day(s) Relative to Start Date	RBC	HGB	HCT	MCV	MCH	MCHC	RDW	RET
		(10 ¹² /L)	(g/L)	(%)	(fL)	(pg)	(g/L)	(%)	(10 ⁹ /L)
1305	-13	6.18	137	45.6	73.8	22.1	300	12.9	250.0
	-6	6.55	147	47.7	72.9	22.5	309	12.3	160.5
	-3	6.69	151	47.9	71.6	22.5	315	12.2	137.3
	1	6.37	142	45.0	70.6	22.3	316	12.2	123.4
	2	5.67	127	41.3	72.8	22.4	307	12.4	144.8
	7	5.71	128	40.2	70.3	22.3	317	12.5	172.0
	14	6.08	132	42.7	70.2	21.8	310	12.2	188.3
	42	6.26	136	42.4	67.7	21.7	320	11.9	95.1

AB001 10 mg/kg	Day(s) Relative to Start Date	RBC	HGB	HCT	MCV	MCH	MCHC	RDW	RET
		(10 ¹² /L)	(g/L)	(%)	(fL)	(pg)	(g/L)	(%)	(10 ⁹ /L)
1407	-13	5.00	115	38.1	76.1	22.9	301	13.8	232.6
	-6	5.55	128	43.9	79.1	23.1	292	13.1	149.8
	-3	5.27	121	39.1	74.3	22.9	308	12.7	170.4
	1	5.53	127	41.3	74.7	23.0	308	12.8	192.1
	2	5.02	114	37.9	75.5	22.7	301	13.1	193.8
	7	4.94	112	36.7	74.3	22.6	304	13.1	272.2
	14	5.22	118	38.9	74.5	22.5	302	12.9	250.5
	42	5.46	124	40.7	74.6	22.7	305	12.3	112.3

FIGURE 8 - continued

AB001 100 mg/kg	Day(s) Relative to Start Date	RBC	HGB	HCT	MCV	MCH	MCHC	RDW	RET
		(10 ^{^12} /L)	(g/L)	(%)	(fL)	(pg)	(g/L)	(%)	(10 ^{^9} /L)
1509	-13	6.12	137	46.9	76.5	22.3	291	12.6	100.6
	-6	6.21	136	45.9	73.9	21.8	295	12.7	116.1
	1	5.89	131	44.0	74.8	22.3	298	12.9	152.1
	2	5.56	121	42.6	76.6	21.7	284	13.1	141.4
	7	5.32	115	39.3	73.8	21.6	292	13.2	258.1
	14	5.94	128	46.4	78.1	21.6	276	12.9	220.7
	42	6.71	147	51.4	76.7	21.9	285	12.6	88.2

Abbreviations:

RBC

Red Blood Cells

HGB

Hemoglobin

HCT

Hematocrit

MCV

Mean Corpuscular Volume

MCH

Mean Corpuscular Hemoglobin

MCHC

Mean Corpuscular Hemoglobin Concentration

RDW

Red Cell Distribution Width

RET

Reticulocytes (Absolute)

FIGURE 9

Male Hematology II

Vehicle Control	Day(s) Relative to Start Date	PLT	WBC	NEUT	LYMP	MONO	EOS	BASO
		(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)
1101	-13	257	16.07	8.51	6.91	0.24	0.17	0.11
	-6	297	18.52	5.88	10.99	0.47	0.83	0.16
	1	295	21.84	8.67	11.78	0.45	0.60	0.14
	2	270	21.24	7.36	12.58	0.41	0.49	0.18
	7	327	18.12	5.08	11.85	0.43	0.50	0.11
	14	386	20.46	8.21	10.86	0.43	0.63	0.16
	42	280	15.70	4.30	10.26	0.38	0.47	0.12

AB001 0.1 mg/kg	Day(s) Relative to Start Date	PLT	WBC	NEUT	LYMP	MONO	EOS	BASO
		(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)
1203	-13	347	9.14	4.36	4.32	0.30	0.07	0.04
	-6	436	11.74	1.82	8.93	0.49	0.30	0.11
	1	387	10.69	1.43	8.52	0.26	0.34	0.07
	2	369	11.81	6.25	4.95	0.37	0.14	0.05
	7	410	9.25	3.78	4.95	0.24	0.19	0.04
	14	436	8.93	2.54	5.80	0.27	0.25	0.03
	42	364	12.90	6.83	5.37	0.38	0.19	0.07

FIGURE 9 - continued

AB001 1 mg/kg	Day(s) Relative to Start Date	PLT	WBC	NEUT	LYMP	MONO	EOS	BASO
		(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)
1305	-13	334	22.46	6.80	14.83	0.32	0.05	0.20
	-6	375	36.24	7.27	26.77	0.72	0.33	0.54
	-3	335	30.61	4.56	24.24	0.44	0.37	0.47
	1	386	35.27	4.59	29.04	0.25	0.31	0.56
	2	330	32.46	7.99	23.17	0.29	0.26	0.38
	7	356	33.46	11.88	20.27	0.33	0.28	0.38
	14	343	34.98	8.03	25.17	0.45	0.47	0.43
	42	306	28.18	4.86	21.89	0.49	0.22	0.32
AB001 10 mg/kg	Day(s) Relative to Start Date	PLT	WBC	NEUT	LYMP	MONO	EOS	BASO
		(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)
1407	-13	375	14.70	4.79	9.52	0.18	0.05	0.09
	-6	389	30.01	13.65	14.59	1.07	0.25	0.26
	-3	382	16.90	1.49	14.57	0.37	0.18	0.16
	1	339	19.36	1.85	16.55	0.36	0.25	0.19
	2	302	17.83	4.11	12.91	0.29	0.21	0.16
	7	375	16.53	4.47	11.34	0.31	0.22	0.11
	14	443	26.94	5.32	20.19	0.50	0.41	0.30
	42	331	22.21	2.61	18.37	0.46	0.29	0.25

FIGURE 9 - continued

AB001 100 mg/kg	Day(s) Relative to Start Date	PLT	WBC	NEUT	LYMP	MONO	EOS	BASO
		(10^9/L)	(10^9/L)	(10^9/L)	(10^9/L)	(10^9/L)	(10^9/L)	(10^9/L)
1509	-13	452	10.38	5.67	3.82	0.70	0.03	0.09
	-6	494	25.43	8.46	15.40	0.65	0.25	0.36
	1	515	20.92	5.45	14.11	0.58	0.37	0.21
	2	457	33.35	25.95	6.15	0.93	0.10	0.15
	7	409	18.22	8.40	8.97	0.47	0.13	0.14
	14	599	20.36	10.09	9.39	0.45	0.19	0.15
	42	510	16.62	7.42	8.33	0.52	0.14	0.12

Abbreviations:

PLT

WBC

NEUT

LYMP

MONO

EOS

BASO

Platelets

White Blood Cells

Neutrophils (Absolute)

Lymphocytes (Absolute)

Monocytes (Absolute)

Eosinophils (Absolute)

Basophils (Absolute)

FIGURE 10
Female Hematology I

Vehicle Control	Day(s) Relative to Start Date	RBC	HGB	HCT	MCV	MCH	MCHC	RDW	RET
		(10 ¹² /L)	(g/L)	(%)	(fL)	(pg)	(g/L)	(%)	(10 ⁹ /L)
2102	-13	6.31	141	46.3	73.4	22.4	305	12.4	122.8
	-6	6.75	148	49.8	73.9	21.9	296	11.9	114.0
	1	6.00	131	44.2	73.7	21.9	297	12.0	121.5
	2	5.32	116	39.0	73.3	21.7	296	12.2	117.1
	7	5.45	119	41.0	75.2	21.8	290	12.5	255.5
	14	5.77	126	42.0	72.8	21.8	300	12.2	196.7
	42	6.18	136	44.3	71.7	22.1	308	11.5	72.4

AB001 0.1 mg/kg	Day(s) Relative to Start Date	RBC	HGB	HCT	MCV	MCH	MCHC	RDW	RET
		(10 ¹² /L)	(g/L)	(%)	(fL)	(pg)	(g/L)	(%)	(10 ⁹ /L)
2204	-13	5.15	129	42.2	82.1	25.0	305	14.4	99.3
	-6	5.31	136	43.1	81.1	25.5	315	14.3	101.3
	1	4.90	127	40.1	81.7	25.9	317	14.2	95.9
	2	4.60	113	37.0	80.4	24.6	306	14.4	107.8
	7	4.59	114	36.9	80.5	24.8	308	14.3	238.0
	14	4.95	123	39.6	80.0	24.8	310	14.3	180.1
	42	5.47	135	43.2	79.0	24.7	313	13.6	99.0

FIGURE 10 - continued

AB001 1 mg/kg	Day(s) Relative to Start Date	RBC	HGB	HCT	MCV	MCH	MCHC	RDW	RET
		(10 ^{^12} /L)	(g/L)	(%)	(fL)	(pg)	(g/L)	(%)	(10 ^{^9} /L)
2306	-13	5.20	125	40.9	78.6	24.0	306	13.1	70.8
	-6	5.06	123	40.1	79.2	24.4	308	13.0	77.4
	1	4.98	121	39.8	79.8	24.3	305	13.1	80.4
	2	4.48	108	35.4	78.9	24.1	305	13.3	74.3
	7	4.55	111	35.8	78.6	24.3	309	13.6	148.8
	14	4.97	121	38.9	78.4	24.3	311	13.1	97.7
	42	5.25	130	40.1	76.4	24.7	323	12.2	40.1

AB001 10 mg/kg	Day(s) Relative to Start Date	RBC	HGB	HCT	MCV	MCH	MCHC	RDW	RET
		(10 ^{^12} /L)	(g/L)	(%)	(fL)	(pg)	(g/L)	(%)	(10 ^{^9} /L)
2408	-13	5.23	128	40.9	78.3	24.4	312	12.1	77.8
	-6	5.30	129	42.4	80.1	24.3	303	11.8	90.7
	1	5.08	126	39.7	78.2	24.9	318	12.2	84.3
	2	4.70	115	37.1	79.0	24.5	310	12.2	97.1
	7	4.50	109	34.8	77.4	24.3	314	12.4	177.5
	14	4.85	117	37.0	76.2	24.1	316	11.9	91.4
	42	5.28	131	39.7	75.2	24.7	329	11.5	46.0

FIGURE 10 - continued

AB001 100 mg/kg	Day(s) Relative to Start Date	RBC	HGB	HCT	MCV	MCH	MCHC	RDW	RET
		(10 ¹² /L)	(g/L)	(%)	(fL)	(pg)	(g/L)	(%)	(10 ⁹ /L)
2510	-13	5.25	112	37.9	72.3	21.3	295	14.6	152.9
	-6	5.42	113	38.9	71.8	20.9	291	14.0	141.6
	1	5.18	109	37.0	71.6	21.1	295	14.1	143.2
	2	4.67	97	34.5	73.9	20.8	282	14.1	141.3
	7	4.84	103	34.0	70.2	21.2	302	14.5	194.5
	14	5.10	108	36.5	71.5	21.1	295	14.1	197.4
	42	5.40	114	36.9	68.3	21.1	309	12.9	100.6

Abbreviations:

RBC

Red Blood Cells

HGB

Hemoglobin

HCT

Hematocrit

MCV

Mean Corpuscular Volume

MCH

Mean Corpuscular Hemoglobin

MCHC

Mean Corpuscular Hemoglobin Concentration

RDW

Red Cell Distribution Width

RET

Reticulocytes (Absolute)

FIGURE 11

Female Hematology II

Vehicle Control	Day(s) Relative to Start Date	PLT	WBC	NEUT	LYMP	MONO	EOS	BASO
		(10^9/L)	(10^9/L)	(10^9/L)	(10^9/L)	(10^9/L)	(10^9/L)	(10^9/L)
2102	-13	409	12.30	8.25	3.64	0.28	0.01	0.06
	-6	465	17.31	7.58	8.49	0.71	0.26	0.13
	1	463	17.06	6.68	9.41	0.47	0.21	0.13
	2	401	19.30	10.82	7.45	0.65	0.16	0.09
	7	466	18.84	10.43	7.52	0.53	0.14	0.10
	14	498	22.49	11.69	9.34	0.80	0.30	0.17
	42	406	15.61	6.94	7.72	0.55	0.18	0.11

AB001 0.1 mg/kg	Day(s) Relative to Start Date	PLT	WBC	NEUT	LYMP	MONO	EOS	BASO
		(10^9/L)	(10^9/L)	(10^9/L)	(10^9/L)	(10^9/L)	(10^9/L)	(10^9/L)
2204	-13	291	10.33	5.08	4.84	0.29	0.02	0.05
	-6	336	17.92	4.68	11.78	0.85	0.26	0.19
	1	314	15.43	4.61	9.67	0.66	0.24	0.13
	2	299	12.04	5.17	6.24	0.33	0.15	0.07
	7	371	12.08	5.61	5.78	0.43	0.11	0.08
	14	343	15.24	5.98	8.20	0.66	0.18	0.11
	42	292	13.39	4.75	7.79	0.47	0.19	0.08

FIGURE 11 - continued

AB001 1 mg/kg	Day(s) Relative to Start Date	PLT	WBC	NEUT	LYMP	MONO	EOS	BASO
		(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)
2306	-13	511	18.73	12.88	5.48	0.23	0.04	0.06
	-6	459	19.87	6.05	12.81	0.52	0.19	0.17
	1	551	16.10	3.61	11.82	0.26	0.21	0.10
	2	464	22.11	11.37	10.04	0.38	0.13	0.11
	7	468	16.55	7.28	8.71	0.32	0.10	0.08
	14	462	19.52	6.17	12.31	0.47	0.31	0.15
	42	426	19.46	6.04	12.49	0.39	0.28	0.16

AB001 10 mg/kg	Day(s) Relative to Start Date	PLT	WBC	NEUT	LYMP	MONO	EOS	BASO
		(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)
2408	-13	283	11.59	4.41	6.73	0.30	0.02	0.05
	-6	304	17.57	6.30	10.31	0.44	0.20	0.17
	1	324	14.88	3.99	9.90	0.42	0.33	0.10
	2	297	18.24	7.51	9.92	0.42	0.17	0.10
	7	294	17.57	10.20	6.80	0.32	0.10	0.08
	14	307	17.15	5.12	10.95	0.58	0.29	0.10
	42	300	21.70	9.11	11.29	0.74	0.22	0.15

FIGURE 11 - continued

AB001 100 mg/kg	Day(s) Relative to Start Date	PLT	WBC	NEUT	LYMP	MONO	EOS	BASO
		(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)	(10 ⁹ /L)
2510	-13	359	13.64	7.64	5.45	0.36	0.07	0.06
	-6	452	21.25	8.50	11.41	0.55	0.51	0.14
	1	418	18.34	6.48	10.88	0.40	0.38	0.09
	2	389	19.60	10.71	8.31	0.28	0.13	0.08
	7	434	18.73	13.53	4.70	0.22	0.17	0.04
	14	433	20.69	10.11	9.67	0.31	0.35	0.11
	42	412	20.23	12.52	6.91	0.35	0.28	0.11

Abbreviations:

PLT

WBC

NEUT

LYMP

MONO

EOS

BASO

Platelets

White Blood Cells

Neutrophils (Absolute)

Lymphocytes (Absolute)

Monocytes (Absolute)

Eosinophils (Absolute)

Basophils (Absolute)

FIGURE 12

Male Coagulation

Vehicle Control	Day(s) Relative to Start Date			
		PT (Seconds)	APTT (Seconds)	FIB (g/L)
1101	-13	10.8	16.7	2.03
	-6	9.8	16.6	1.61
	2	9.8	16.7	2.22
	42	9.8	16.3	1.80

AB001 0.1 mg/kg	Day(s) Relative to Start Date			
		PT (Seconds)	APTT (Seconds)	FIB (g/L)
1203	-13	9.8	18.7	1.84
	-6	9.0	20.1	1.80
	2	9.1	18.5	2.17
	42	8.6	19.7	2.07

AB001 1 mg/kg	Day(s) Relative to Start Date			
		PT (Seconds)	APTT (Seconds)	FIB (g/L)
1305	-13	10.7	18.6	2.65
	-6	9.5	19.0	2.49
	2	9.6	18.9	2.78
	42	9.4	20.0	3.54

AB001 10 mg/kg	Day(s) Relative to Start Date			
		PT (Seconds)	APTT (Seconds)	FIB (g/L)
1407	-13	9.3	16.9	2.53
	-6	9.1	17.7	2.65
	2	9.1	16.8	2.78
	42	9.0	18.1	2.61

FIGURE 12 - continued

AB001 100 mg/kg Day(s) Relative to Start Date		PT	APTT	FIB
		(Seconds)	(Seconds)	(g/L)
1509	-13	11.5	20.4	2.74
	-6	10.2	19.4	2.11
	2	11.1	19.6	4.02
	42	10.6	19.8	2.31

Abbreviations:

PT	Prothrombin Time
APTT	Activated Partial Thromboplastin Time
FIB	Fibrinogen

FIGURE 13**Female Coagulation**

Vehicle Control	Day(s) Relative to Start Date	PT	APTT	FIB
		(Seconds)	(Seconds)	(g/L)
2102	-13	10.8	17.4	2.19
	-6	9.9	16.7	2.03
	2	10.1	17.6	2.93
	42	9.8	18.3	2.20

AB001 0.1 mg/kg	Day(s) Relative to Start Date	PT	APTT	FIB
		(Seconds)	(Seconds)	(g/L)
2204	-13	10.2	16.8	2.35
	-6	9.3	16.9	2.39
	2	9.4	17.5	2.93
	42	9.2	18.1	2.54

AB001 1 mg/kg	Day(s) Relative to Start Date	PT	APTT	FIB
		(Seconds)	(Seconds)	(g/L)
2306	-13	9.3	15.9	2.32
	-6	8.8	14.6	2.03
	2	9.3	15.7	2.57
	42	8.5	14.8	2.15

AB001 10 mg/kg	Day(s) Relative to Start Date	PT	APTT	FIB
		(Seconds)	(Seconds)	(g/L)
2408	-13	10.6	18.2	1.93
	-6	9.0	17.3	1.95
	2	9.2	17.9	2.11
	42	8.8	18.6	2.34

FIGURE 13 - continued

AB001 100 mg/kg Day(s) Relative to Start Date		PT	APTT	FIB
		(Seconds)	(Seconds)	(g/L)
2510	-13	10.2	19.9	1.86
	-6	9.5	19.1	1.80
	2	9.2	20.0	2.11
	42	9.3	17.4	2.26

Abbreviations:

PT Prothrombin Time
APTT Activated Partial Thromboplastin Time
FIB Fibrinogen

FIGURE 14**Male Chemistry I**

Vehicle	Day(s) Relative to Start Date	ALT	AST	ALP	GGT	CK	TBIL	GLU
		(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(μ mol/L)	(mmol/L)
1101	-13	32.9	45.5	1122	61	175	5.9	3.63
	-6	20.7	32.0	897	54	222	2.5	7.07
	2	34.3	72.3	766	53	221	2.5	6.21
	7	24.5	33.8	749	49	143	1.8	6.03
	14	19.2	27.6	783	49	195	0.7	6.96
	42	20.9	32.3	946	59	142	2.1	5.51

AB001 0.1 mg/kg	Day(s) Relative to Start Date	ALT	AST	ALP	GGT	CK	TBIL	GLU
		(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(μ mol/L)	(mmol/L)
1203	-13	49.9	72.3	799	95	302	3.1	5.77
	-6	28.0	39.9	745	84	505	1.5	7.41
	2	54.8	93.5	702	77	715	1.6	5.92
	7	29.7	38.1	747	71	210	0.6	6.44
	14	26.0	37.2	803	74	318	0.6	5.12
	42	24.8	40.3	862	77	326	0.8	6.15

AB001 1 mg/kg	Day(s) Relative to Start Date	ALT	AST	ALP	GGT	CK	TBIL	GLU
		(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(μ mol/L)	(mmol/L)
1305	-13	42.2	55.5	681	140	472	5.4	5.68
	-6	28.7	37.2	534	106	313	3.0	6.84
	2	43.9	75.8	513	97	753	2.7	6.00
	7	63.4	60.0	508	90	745	2.6	5.34
	14	31.8	32.4	531	93	213	1.1	5.77
	42	23.1	34.6	529	89	295	2.6	6.17

FIGURE 14 - conitnued

AB001 10 mg/kg								
Day(s) Relative toStart Date		ALT (U/L)	AST (U/L)	ALP (U/L)	GGT (U/L)	CK (U/L)	TBIL (μ mol /L)	GLU (mmol /L)
1407	-13	64.6	71.1	601	87	664	3.2	6.84
	-6	62.7	51.4	565	87	416	2.6	6.50
	2	61.0	108.5	525	76	471	2.0	6.83
	7	51.4	51.4	490	70	359	2.3	6.30
	14	42.8	38.4	501	72	234	1.2	5.83
	42	38.7	38.8	569	82	257	1.8	6.97

AB001 100 mg/kg								
Day(s) Relative toStart Date		ALT (U/L)	AST (U/L)	ALP (U/L)	GGT (U/L)	CK (U/L)	TBIL (μ mol /L)	GLU (mmol /L)
1509	-13	92.7	71.8	613	80	188	3.2	5.62
	-6	55.7	34.4	499	69	184	1.4	7.21
	2	257.8	866.5	581	82	1213 5	2.9	7.19
	7	272.2	117.9	593	71	614	1.4	6.76
	14	86.2	44.8	680	83	179	0.7	7.43
	42	60.3	46.1	827	98	281	1.5	7.82

Abbreviations:

ALT	Alanine Aminotransferase
AST	Aspartate Aminotransferase
ALP	Alkaline Phosphatase
GGT	Gamma Glutamyl Transferase
CK	Creatine Kinase
TBIL	Total Bilirubin
GLU	Glucose

FIGURE 15

Male Chemistry II

Vehicle	Day(s) Relative to Start Date	UREA	CREA	TG	CHOL	TP	ALB	GLOB
		(mmol/L)	(μ mol/L)	(mmol/L)	(mmol/L)	(g/L)	(g/L)	(g/L)
1101	-13	8.6	68	0.44	3.61	81.7	45.2	36.5
	-6	8.4	62	0.36	3.58	74.0	42.1	31.9
	2	8.2	64	0.32	3.33	73.3	42.4	30.9
	7	7.9	64	0.50	3.73	73.6	41.4	32.2
	14	8.8	66	0.42	3.92	72.5	40.8	31.7
	42	7.6	61	0.56	3.35	75.9	43.2	32.7

AB001 0.1 mg/kg	Day(s) Relative to Start Date	UREA	CREA	TG	CHOL	TP	ALB	GLOB
		(mmol/L)	(μ mol/L)	(mmol/L)	(mmol/L)	(g/L)	(g/L)	(g/L)
1203	-13	8.3	69	0.63	2.95	74.1	46.5	27.6
	-6	7.7	63	0.71	3.59	75.0	45.0	30.0
	2	5.5	63	0.53	2.75	73.2	45.8	27.4
	7	6.9	67	0.52	3.07	73.8	44.9	28.9
	14	7.5	71	0.59	3.20	70.4	42.9	27.5
	42	7.2	69	1.09	3.41	75.0	46.0	29.0

AB001 1 mg/kg	Day(s) Relative to Start Date	UREA	CREA	TG	CHOL	TP	ALB	GLOB
		(mmol/L)	(μ mol/L)	(mmol/L)	(mmol/L)	(g/L)	(g/L)	(g/L)
1305	-13	7.0	67	0.35	3.33	82.8	48.4	34.4
	-6	5.5	56	0.22	4.11	78.4	45.6	32.8
	2	5.1	59	0.26	3.29	78.5	45.5	33.0
	7	5.7	61	0.30	3.78	79.4	47.3	32.1
	14	5.5	60	0.22	4.05	76.4	46.0	30.4
	42	5.8	59	0.39	4.42	81.0	45.6	35.4

FIGURE 15 - continued

AB001 10 mg/kg		UREA	CREA	TG	CHOL	TP	ALB	GLOB
Day(s) Relative toStart Date		(mmol/ L)	(μ mol /L)	(mmol /L)	(mmol/ L)	(g/L)	(g/L)	(g/L)
1407	-13	7.4	69	0.46	3.50	76.6	44.1	32.5
	-6	6.5	65	0.98	3.84	79.6	45.6	34.0
	2	5.4	70	0.49	3.66	77.6	43.8	33.8
	7	6.3	74	0.39	3.62	75.7	45.1	30.6
	14	6.0	67	0.43	4.12	73.7	44.2	29.5
	42	6.2	74	1.20	3.94	74.5	44.9	29.6

AB001 100 mg/kg		UREA	CREA	TG	CHOL	TP	ALB	GLOB
Day(s) Relative toStart Date		(mmol/ L)	(μ mol /L)	(mmol /L)	(mmol/ L)	(g/L)	(g/L)	(g/L)
1509	-13	6.5	72	0.35	3.64	89.9	42.8	47.1
	-6	6.3	73	0.65	3.67	86.5	40.0	46.5
	2	6.0	71	0.44	3.11	83.3	42.0	41.3
	7	6.0	73	0.59	3.26	78.9	43.3	35.6
	14	6.4	70	0.48	4.20	77.8	45.5	32.3
	42	6.2	76	0.87	4.38	75.2	47.8	27.4

Abbreviations:

UREA	Urea
CREA	Creatinine
TG	Triglycerides
CHOL	Total Cholesterol
TP	Total Protein
ALB	Albumin
GLOB	Globulin

FIGURE 16

Male Chemistry III

Vehicle	Day(s) Relative to Start Date							
		A/G	Na (mmol/L)	K (mmol/L)	Cl (mmol/L)	IgA (g/L)	IgG (g/L)	IgM (g/L)
1101	-13	1.2	153	4.45	108.3	1.69	11.96	0.76
	-6	1.3	153	3.74	104.0	1.54	10.08	0.66
	2	1.4	154	4.14	108.1	1.43	9.25	0.59
	7	1.3	150	3.59	105.5	1.50	10.29	0.54
	14	1.3	148	4.04	106.3	1.46	9.80	0.54
	42	1.3	146	3.41	104.0	1.57	11.28	0.66

AB001 0.1 mg/kg	Day(s) Relative to Start Date							
		A/G	Na (mmol/L)	K (mmol/L)	Cl (mmol/L)	IgA (g/L)	IgG (g/L)	IgM (g/L)
1203	-13	1.7	156	4.20	112.4	0.81	8.44	0.51
	-6	1.5	155	5.03	106.7	0.93	8.27	0.63
	2	1.7	150	3.87	106.0	0.84	7.48	0.56
	7	1.6	150	3.82	106.8	0.86	7.41	0.52
	14	1.6	149	3.87	108.0	0.93	7.88	0.57
	42	1.6	147	3.58	104.7	1.09	9.06	0.64

AB001 1 mg/kg	Day(s) Relative to Start Date							
		A/G	Na (mmol/L)	K (mmol/L)	Cl (mmol/L)	IgA (g/L)	IgG (g/L)	IgM (g/L)
1305	-13	1.4	155	4.52	111.5	0.95	11.38	1.49
	-6	1.4	149	4.15	104.7	1.00	10.83	1.83
	2	1.4	148	3.81	106.0	0.91	10.62	1.69
	7	1.5	149	4.26	106.5	0.81	9.67	1.39
	14	1.5	149	4.01	106.7	0.56	8.91	1.13
	42	1.3	144	3.67	102.8	0.88	11.94	1.57

FIGURE 16 - continued

AB001 10 mg/kg		A/G	Na	K	Cl	IgA	IgG	IgM
Day(s) Relative to Start Date			(mmol/L)	(mmol/ L)	(mmol/L)	(g/L)	(g/L)	(g/L)
1407	-13	1.4	152	4.08	108.0	0.75	10.20	0.74
	-6	1.3	152	3.60	103.1	0.84	9.93	0.85
	2	1.3	148	3.41	106.0	0.84	9.47	0.83
	7	1.5	147	3.49	105.8	0.69	8.96	0.74
	14	1.5	145	3.75	102.3	0.58	8.21	0.64
	42	1.5	146	3.07	98.7	0.66	9.34	0.60

AB001 100 mg/kg		A/G	Na	K	Cl	IgA	IgG	IgM
Day(s) Relative to Start Date			(mmol/L)	(mmol/ L)	(mmol/L)	(g/L)	(g/L)	(g/L)
1509	-13	0.9	155	4.72	106.1	1.03	17.31	1.65
	-6	0.9	148	4.46	102.1	0.95	16.38	2.75
	2	1.0	150	4.51	103.9	0.76	14.11	1.70
	7	1.2	152	4.68	106.9	0.60	10.86	1.20
	14	1.4	153	5.03	104.6	0.44	9.21	0.82
	42	1.7	155	5.04	104.2	0.24	7.24	0.49

Abbreviations:

A/G	Albumin/Globulin Ratio
Na	Sodium
K	Potassium Chloride
Cl	Chloride
IgA	Immunoglobulin A
IgG	Immunoglobulin G
IgM	Immunoglobulin M

FIGURE 17

Female Chemistry I

Vehicle Control	Day(s) Relative to Start Date	ALT	AST	ALP	GGT	CK	TBIL	GLU
		(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(μ mol/L)	(mmol/L)
2102	-	17.9	53.3	865	64	225	3.1	3.92
	13							
	-6	11.5	36.3	715	57	270	1.7	7.15
	2	29.2	208.0	688	50	3564	1.0	5.01
	7	58.2	55.1	623	50	218	0.8	6.95
	14	14.4	35.4	718	52	201	0.4	7.58
	42	10.7	41.9	708	56	144	1.2	5.53

AB001 0.1 mg/kg	Day(s) Relative to Start Date	ALT	AST	ALP	GGT	CK	TBIL	GLU
		(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(μ mol/L)	(mmol/L)
2204	-	43.0	49.3	365	55	225	3.1	3.67
	13							
	-6	28.5	28.3	344	57	153	1.5	5.76
	2	52.6	91.0	330	54	803	1.8	5.47
	7	82.2	62.8	320	54	508	1.6	5.54
	14	33.9	31.4	353	56	185	0.7	5.01
	42	30.1	38.1	406	61	203	1.6	6.41

AB001 1 mg/kg	Day(s) Relative to Start Date	ALT	AST	ALP	GGT	CK	TBIL	GLU
		(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(μ mol/L)	(mmol/L)
2306	-	41.1	60.4	404	80	715	3.5	4.90
	13							
	-6	28.5	30.5	326	79	158	2.2	5.32
	2	52.8	94.5	320	80	753	1.0	6.12
	7	39.5	37.3	319	77	217	1.5	4.76
	14	31.2	32.5	332	81	170	1.0	5.82
	42	25.7	35.9	403	92	164	1.2	5.14

FIGURE 17 - continued

AB001 10 mg/kg								
		ALT	AST	ALP	GGT	CK	TBIL	GLU
Day(s) Relative to Start Date		(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(μ mol /L)	(mmol /L)
2408	-13	53.1	71.0	680	56	394	4.2	4.50
	-6	44.7	39.3	581	54	257	2.8	6.27
	2	51.2	71.7	562	54	331	2.6	7.90
	7	36.6	34.9	527	53	158	2.3	5.80
	14	40.7	33.8	524	55	166	1.8	6.63
	42	33.7	39.6	706	57	233	2.1	4.41

AB001 100 mg/kg								
		ALT	AST	ALP	GGT	CK	TBIL	GLU
Day(s) Relative to Start Date		(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(μ mol /L)	(mmol /L)
2510	-13	29.7	62.0	397	67	154	3.2	5.88
	-6	16.4	31.0	328	62	106	1.8	7.48
	2	21.8	81.9	360	62	153	0.9	7.50
	7	22.9	38.6	331	62	109	1.0	6.71
	14	19.0	36.0	331	62	123	0.9	7.36
	42	15.8	33.2	372	61	132	1.5	6.38

Abbreviations:

ALT	Alanine Aminotransferase
AST	Aspartate Aminotransferase
ALP	Alkaline Phosphatase
GGT	Gamma Glutamyl Transferase
CK	Creatine Kinase
TBIL	Total Bilirubin
GLU	Glucose

FIGURE 18**Female Chemistry II**

Veh icle Con trol	Day(s) Relative toStart Date	UREA	CREA	TG	CHOL	TP	ALB	GLOB
		(mmol/ L)	(μ mol /L)	(mmol /L)	(mmol/ L)	(g/L)	(g/L)	(g/L)
21 02	-13	7.4	37	0.49	2.47	78.1	45.4	32.7
	-6	7.2	44	0.40	2.30	73.1	43.2	29.9
	2	5.6	36	0.29	2.07	69.2	40.5	28.7
	7	5.2	37	0.22	2.34	69.3	41.2	28.1
	14	6.0	35	0.30	2.72	70.2	40.7	29.5
	42	5.3	36	0.59	2.50	71.6	43.5	28.1

AB001 0.1 mg/kg	Day(s) Relative toStart Date	UREA	CREA	TG	CHOL	TP	ALB	GLOB
		(mmol/ L)	(μ mol /L)	(mmol /L)	(mmol/ L)	(g/L)	(g/L)	(g/L)
22 04	-13	6.3	63	0.47	3.23	79.8	42.4	37.4
	-6	6.9	59	0.78	3.38	76.6	42.2	34.4
	2	5.2	63	0.44	3.18	73.1	38.8	34.3
	7	6.9	63	0.58	3.40	78.0	42.2	35.8
	14	6.6	61	0.46	3.71	74.6	39.9	34.7
	42	7.4	65	0.88	3.50	79.5	44.4	35.1

AB001 1 mg/kg	Day(s) Relative toStart Date	UREA	CREA	TG	CHOL	TP	ALB	GLOB
		(mmol/ L)	(μ mol /L)	(mmol /L)	(mmol/ L)	(g/L)	(g/L)	(g/L)
23 06	-13	5.9	54	0.38	3.69	79.5	43.7	35.8
	-6	5.6	52	0.29	3.82	75.2	41.5	33.7
	2	4.9	49	0.19	3.42	75.6	43.1	32.5
	7	5.0	55	0.21	3.96	74.1	44.6	29.5
	14	5.8	50	0.24	4.42	73.4	43.7	29.7
	42	5.6	48	0.32	4.28	75.2	44.1	31.1

FIGURE 18 - continued

AB001 10 mg/kg		UREA	CREA	TG	CHOL	TP	ALB	GLOB
Day(s) Relative toStart Date		(mmol/ L)	(μ mol /L)	(mmol /L)	(mmol/ L)	(g/L)	(g/L)	(g/L)
2408	-13	11.8	60	0.33	3.52	73.2	44.8	28.4
	-6	7.8	56	0.39	3.97	73.8	43.7	30.1
	2	7.6	59	0.31	3.72	72.5	44.6	27.9
	7	7.2	59	0.18	4.03	72.1	45.9	26.2
	14	7.3	59	0.21	4.50	69.8	44.5	25.3
	42	9.0	65	0.49	4.78	70.9	44.2	26.7
AB001 100 mg/kg		UREA	CREA	TG	CHOL	TP	ALB	GLOB
Day(s) Relative toStart Date		(mmol/ L)	(μ mol /L)	(mmol /L)	(mmol/ L)	(g/L)	(g/L)	(g/L)
2510	-13	9.8	73	0.63	2.42	78.2	40.7	37.5
	-6	7.7	66	0.64	2.36	73.1	38.9	34.2
	2	6.6	64	0.62	2.25	74.0	38.8	35.2
	7	7.9	81	0.70	2.67	73.7	41.8	31.9
	14	8.2	65	0.49	2.68	70.6	42.4	28.2
	42	7.3	72	0.64	2.35	66.7	40.4	26.3

Abbreviations:

UREA	Urea
CREA	Creatinine
TG	Triglycerides
CHOL	Total Cholesterol
TP	Total Protein
ALB	Albumin
GLOB	Globulin

FIGURE 19**Female Chemistry III**

Vehicle Control	Day(s) Relative to Start Date	A/G	Na	K	Cl	IgA	IgG	IgM
			(mmol /L)	(mmol /L)	(mmol /L)	(g/L)	(g/L)	(g/L)
2102	-13	1.4	153	4.10	109.4	0.89	9.86	0.62
	-6	1.4	152	4.52	106.6	0.96	8.70	0.68
	2	1.4	148	3.61	108.6	0.84	7.70	0.57
	7	1.5	148	3.72	108.6	0.92	7.93	0.58
	14	1.4	148	3.40	107.5	1.00	8.28	0.66
	42	1.5	145	3.41	105.2	1.02	9.33	0.67

AB001 0.1 mg/kg	Day(s) Relative to Start Date	A/G	Na	K	Cl	IgA	IgG	IgM
			(mmol /L)	(mmol /L)	(mmol /L)	(g/L)	(g/L)	(g/L)
2204	-13	1.1	155	4.49	114.2	1.96	11.39	1.60
	-6	1.2	150	4.64	107.6	1.98	10.79	1.81
	2	1.1	147	3.94	109.5	1.65	9.50	1.40
	7	1.2	150	4.10	110.7	1.68	10.24	1.46
	14	1.1	150	4.27	110.4	1.72	10.01	1.53
	42	1.3	145	3.52	104.5	2.06	12.23	1.85

AB001 1 mg/kg	Day(s) Relative to Start Date	A/G	Na	K	Cl	IgA	IgG	IgM
			(mmol /L)	(mmol /L)	(mmol /L)	(g/L)	(g/L)	(g/L)
2306	-13	1.2	151	4.25	110.9	1.39	9.85	1.59
	-6	1.2	146	4.25	104.7	1.33	9.22	1.49
	2	1.3	145	4.10	107.7	1.25	8.86	1.34
	7	1.5	146	3.71	106.5	1.07	8.53	1.13
	14	1.5	146	4.17	105.2	0.87	8.30	0.90
	42	1.4	144	3.46	103.8	1.05	9.95	0.99

FIGURE 19 - continued

AB001 10 mg/kg		A/G	Na	K	Cl	IgA	IgG	IgM
Day(s) Relative toStart Date			(mmol /L)	(mmol /L)	(mmol /L)	(g/L)	(g/L)	(g/L)
2408	-13	1.6	152	3.36	111.7	0.87	9.36	0.91
	-6	1.5	150	4.26	105.1	0.90	9.12	0.96
	2	1.6	145	3.54	103.1	0.82	9.01	0.87
	7	1.8	145	3.34	105.3	0.63	8.01	0.65
	14	1.8	146	3.62	104.5	0.45	7.15	0.55
	42	1.7	144	3.28	102.2	0.35	9.04	0.47

AB001 100 mg/kg		A/G	Na	K	Cl	IgA	IgG	IgM
Day(s) Relative toStart Date			(mmol /L)	(mmol /L)	(mmol /L)	(g/L)	(g/L)	(g/L)
2510	-13	1.1	152	3.68	112.5	0.96	12.59	0.95
	-6	1.1	148	3.63	107.0	0.98	12.24	0.93
	2	1.1	146	3.77	107.3	0.95	13.16	0.86
	7	1.3	146	3.92	110.2	0.72	10.76	0.74
	14	1.5	147	3.64	109.0	0.47	9.24	0.54
	42	1.5	145	3.23	107.3	0.13	7.71	0.24

Abbreviations:

A/G	Albumin/Globulin Ratio
Na	Sodium
K	Potassium Chloride
Cl	Chloride
IgA	Immunoglobulin A
IgG	Immunoglobulin G
IgM	Immunoglobulin M

FIGURE 20**Male Cytokine Profile I**

Vehicle		IL-2	IL-4	IL-6	IL-10	IFN- γ
Control	Day(s) Relative to Start Date	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
1101	1 (PrDOM)	0.000	0.000	0.000	0.000	0.000
	1 (1HPD)	0.000	0.000	61.490	0.000	0.000
	1 (3HPD)	0.000	0.000	13.070	0.000	0.000
	1 (8HPD)	0.000	2.000	10.280	0.000	0.000
	2	0.000	0.420	0.000	0.000	0.000
	3	0.000	0.000	0.000	0.000	0.000
	7	0.000	0.000	0.000	0.000	0.000

AB001 0.1 mg/kg		IL-2	IL-4	IL-6	IL-10	IFN- γ
	Day(s) Relative to Start Date	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
1203	1 (PrDOM)	0.000	0.000	0.000	0.000	0.000
	1 (1HPD)	0.000	0.000	22.110	0.000	0.000
	1 (3HPD)	0.000	0.000	16.130	0.000	0.000
	1 (8HPD)	0.000	0.000	19.480	0.000	0.000
	2	0.000	0.000	1.990	0.000	0.000
	3	0.000	0.000	0.000	0.000	0.000
	7	0.000	0.000	0.000	0.000	0.000

AB001 1 mg/kg		IL-2	IL-4	IL-6	IL-10	IFN- γ
	Day(s) Relative to Start Date	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
1305	1 (PrDOM)	0.000	0.000	0.000	0.000	0.000
	1 (1HPD)	0.000	0.000	88.650	1.780	0.000
	1 (3HPD)	0.000	0.000	28.720	0.000	0.000
	1 (8HPD)	0.000	0.000	6.200	0.000	0.000
	2	0.000	0.000	0.000	0.000	0.000
	3	0.000	0.000	0.420	0.000	0.000
	7	0.000	0.000	0.000	0.000	0.000

FIGURE 20 - continued

AB001 10 mg/kg		IL-2	IL-4	IL-6	IL-10	IFN- γ
Day(s) Relative to Start Date		(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
1407	1 (PrD0M)	0.000	0.000	0.000	0.000	0.000
	1 (1HPD)	0.000	0.000	23.140	0.000	0.000
	1 (3HPD)	0.000	0.000	14.430	0.000	0.000
	1 (8HPD)	0.000	0.000	0.000	0.000	0.000
	2	0.000	0.000	0.000	0.000	0.000
	3	0.000	0.000	0.000	0.000	0.000
	7	0.000	0.000	0.000	0.000	0.000

AB001 100 mg/kg		IL-2	IL-4	IL-6	IL-10	IFN- γ
Day(s) Relative to Start Date		(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
1509	1 (PrD0M)	0.000	0.000	0.000	0.000	0.000
	1 (1HPD)	0.000	3.240	108.130	86.190	10.180
	1 (3HPD)	0.000	3.060	103.970	0.000	13.000
	1 (8HPD)	0.000	0.870	52.660	25.630	8.950
	2	0.000	0.000	30.330	0.000	6.820
	3	0.000	0.000	3.150	20.440	0.000
	7	0.000	0.000	0.000	0.000	0.000

Abbreviation

nPrD0M

1HPD

3HPD

8HPD

Description

Pre Dose 0 min

1 Hr Post Dose

3 Hr Post Dose

8 Hr Post Dose

FIGURE 21**Male Cytokine Panel II**

Vehicle						
Control	Day(s) Relative to Start Date	TNF- α	IL-17A	IL-5	IL-13	IL-21
		(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
1101	1 (PrDOM)	0.000	0.000	0.00	0.00	0.00
	1 (1HPD)	0.000	0.000	0.00	0.00	0.00
	1 (3HPD)	0.000	0.000	0.00	0.00	0.00
	1 (8HPD)	0.000	0.000	0.00	0.00	0.00
	2	0.000	0.000	0.00	0.00	0.00
	3	0.000	0.000	0.00	0.00	0.00
	7	0.000	0.000	0.00	0.00	0.00

AB001 0.1 mg/kg						
	Day(s) Relative to Start Date	TNF- α	IL-17A	IL-5	IL-13	IL-21
		(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
1203	1 (PrDOM)	0.000	0.000	0.00	0.00	0.00
	1 (1HPD)	0.000	0.000	0.00	0.00	0.00
	1 (3HPD)	0.000	0.000	0.00	0.00	0.00
	1 (8HPD)	0.000	0.000	0.00	0.00	0.00
	2	0.000	0.000	0.00	0.00	0.00
	3	0.000	0.000	0.00	0.00	0.00
	7	0.000	0.000	0.00	0.00	0.00

AB001 1 mg/kg						
	Day(s) Relative to Start Date	TNF- α	IL-17A	IL-5	IL-13	IL-21
		(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
1305	1 (PrDOM)	0.000	0.000	0.00	0.00	0.00
	1 (1HPD)	0.000	0.000	0.00	0.00	0.00
	1 (3HPD)	0.000	0.000	0.00	0.00	0.00
	1 (8HPD)	0.000	0.000	0.00	0.00	0.00
	2	0.000	0.000	0.00	0.00	0.00
	3	0.000	0.000	0.00	0.00	0.00
	7	0.000	0.000	0.00	0.00	0.00

FIGURE 21- continued

AB001 10 mg/kg						
Day(s) Relative to Start Date		TNF- α (pg/mL)	IL-17A (pg/mL)	IL-5 (pg/mL)	IL-13 (pg/mL)	IL-21 (pg/mL)
1407	1 (PrD0M)	0.000	0.000	0.00	0.00	0.00
	1 (1HPD)	0.000	0.000	0.00	0.00	0.00
	1 (3HPD)	0.000	0.000	0.00	0.00	0.00
	1 (8HPD)	0.000	0.000	0.00	0.00	0.00
	2	0.000	0.000	0.00	0.00	0.00
	3	0.000	0.000	0.00	0.00	0.00
	7	0.000	0.000	0.00	0.00	0.00

AB001 100 mg/kg						
Day(s) Relative to Start Date		TNF- α (pg/mL)	IL-17A (pg/mL)	IL-5 (pg/mL)	IL-13 (pg/mL)	IL-21 (pg/mL)
1509	1 (PrD0M)	0.000	0.000	0.00	0.00	0.00
	1 (1HPD)	0.000	6.660	0.00	0.00	0.00
	1 (3HPD)	0.000	3.330	0.00	0.00	0.00
	1 (8HPD)	0.000	5.190	0.00	0.00	0.00
	2	0.000	0.000	0.00	0.00	0.00
	3	0.000	0.000	0.00	0.00	0.00
	7	0.000	0.000	0.00	0.00	0.00

Abbreviation

nPrD0M

1HPD

3HPD

8HPD

Description

Pre Dose 0 min

1 Hr Post Dose

3 Hr Post Dose

8 Hr Post Dose

FIGURE 22

Female Cytokine Panel I

Vehicle Control		IL-2	IL-4	IL-6	IL-10	IFN- γ
Day(s) Relative to Start Date		(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
2102	1 (PrDOM)	0.000	0.420	0.000	0.000	0.000
	1 (1HPD)	0.000	3.240	46.950	7.560	0.000
	1 (3HPD)	0.000	4.820	34.150	7.560	8.110
	1 (8HPD)	0.000	5.030	17.610	1.780	8.110
	2	0.000	0.720	0.000	0.000	0.000
	3	0.000	0.000	10.520	0.000	0.000
	7	0.000	1.340	0.000	20.440	0.000

AB001 0.1 mg/kg		IL-2	IL-4	IL-6	IL-10	IFN- γ
Day(s) Relative to Start Date		(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
2204	1 (PrDOM)	0.000	0.000	0.000	0.000	0.000
	1 (1HPD)	0.000	0.000	64.900	18.750	0.000
	1 (3HPD)	0.000	0.000	27.940	0.000	0.000
	1 (8HPD)	0.000	2.170	8.170	0.000	0.000
	2	0.000	2.340	0.000	0.000	0.000
	3	0.000	0.720	0.000	10.630	0.000
	7	0.000	0.000	0.000	0.000	0.000

AB001 1 mg/kg		IL-2	IL-4	IL-6	IL-10	IFN- γ
Day(s) Relative to Start Date		(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
2306	1 (PrDOM)	0.000	2.170	0.000	0.000	5.460
	1 (1HPD)	0.000	0.000	55.080	1.780	0.000
	1 (3HPD)	0.000	0.000	29.120	0.000	0.000
	1 (8HPD)	0.000	0.870	15.270	0.000	4.460
	2	0.000	0.280	0.000	0.000	3.350
	3	0.000	0.000	0.000	0.000	0.000
	7	0.000	2.520	0.000	0.000	8.530

FIGURE 22- continued

AB001 10 mg/kg		IL-2	IL-4	IL-6	IL-10	IFN- γ
Day(s) Relative to Start Date		(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
2408	1 (PrD0M)	0.000	0.000	0.000	0.000	0.000
	1 (1HPD)	0.000	0.000	13.070	0.000	0.000
	1 (3HPD)	0.000	0.000	0.000	0.000	0.000
	1 (8HPD)	0.000	0.000	0.000	0.000	0.000
	2	0.000	0.000	0.000	0.000	0.000
	3	0.000	2.170	0.000	0.000	0.000
	7	0.000	0.000	0.000	0.000	0.000

AB001 100 mg/kg		IL-2	IL-4	IL-6	IL-10	IFN- γ
Day(s) Relative to Start Date		(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
2510	1 (PrD0M)	0.000	0.000	0.000	0.000	0.000
	1 (1HPD)	0.000	1.180	32.840	0.000	0.000
	1 (3HPD)	0.000	2.170	7.280	0.000	8.110
	1 (8HPD)	0.000	0.000	0.000	0.000	0.000
	2	0.000	0.000	0.000	0.000	0.000
	3	0.000	0.000	0.000	0.000	0.000
	7	0.000	2.170	0.000	4.610	10.180

Abbreviation

nPrD0M

1HPD

3HPD

8HPD

Description

Pre Dose 0 min

1 Hr Post Dose

3 Hr Post Dose

8 Hr Post Dose

FIGURE 23

Female Cytokine Panel I

Vehicle Control		TNF- α	IL-17A	IL-5	IL-13	IL-21
Day(s) Relative to Start Date		(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
2102	1 (PrDOM)	0.000	0.000	0.00	0.00	0.00
	1 (1HPD)	0.000	5.960	0.00	0.00	0.00
	1 (3HPD)	0.000	10.280	0.00	0.00	0.00
	1 (8HPD)	0.000	9.720	0.00	0.00	0.00
	2	0.000	0.000	0.00	0.00	0.00
	3	0.000	0.000	0.00	0.00	0.00
	7	0.000	13.950	0.00	0.00	0.00

AB001 0.1 mg/kg		TNF- α	IL-17A	IL-5	IL-13	IL-21
Day(s) Relative to Start Date		(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
2204	1 (PrDOM)	0.000	0.000	0.00	0.00	0.00
	1 (1HPD)	0.000	5.190	0.00	0.00	0.00
	1 (3HPD)	0.000	0.000	0.00	0.00	0.00
	1 (8HPD)	0.000	0.000	0.00	0.00	0.00
	2	0.000	0.000	0.00	0.00	0.00
	3	0.000	4.340	0.00	0.00	0.00
	7	0.000	0.000	0.00	0.00	0.00

AB001 1 mg/kg		TNF- α	IL-17A	IL-5	IL-13	IL-21
Day(s) Relative to Start Date		(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
2306	1 (PrDOM)	0.000	10.830	0.00	0.00	0.00
	1 (1HPD)	0.000	0.000	0.00	0.00	0.00
	1 (3HPD)	0.000	0.000	0.00	0.00	0.00
	1 (8HPD)	0.000	8.560	0.00	0.00	0.00
	2	0.000	7.330	0.00	0.00	0.00
	3	0.000	0.000	0.00	0.00	0.00
	7	0.000	11.890	0.00	0.00	0.00

FIGURE 23- continued

AB001 10 mg/kg		TNF- α	IL-17A	IL-5	IL-13	IL-21
Day(s) Relative to Start Date		(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
2408	1 (PrD0M)	0.000	0.000	0.00	0.00	0.00
	1 (1HPD)	0.000	0.000	0.00	0.00	0.00
	1 (3HPD)	0.000	0.000	0.00	0.00	0.00
	1 (8HPD)	0.000	0.000	0.00	0.00	0.00
	2	0.000	0.000	0.00	0.00	0.00
	3	0.000	0.000	0.00	0.00	0.00
	7	0.000	0.000	0.00	0.00	0.00

AB001 100 mg/kg		TNF- α	IL-17A	IL-5	IL-13	IL-21
Day(s) Relative to Start Date		(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)	(pg/mL)
2510	1 (PrD0M)	0.000	0.000	0.00	0.00	0.00
	1 (1HPD)	0.000	5.960	0.00	0.00	0.00
	1 (3HPD)	0.000	13.440	0.00	0.00	0.00
	1 (8HPD)	0.000	0.000	0.00	0.00	0.00
	2	0.000	0.000	0.00	0.00	0.00
	3	0.000	0.000	0.00	0.00	0.00
	7	0.000	11.890	0.00	0.00	0.00

Abbreviation

nPrD0M

1HPD

3HPD

8HPD

Description

Pre Dose 0 min

1 Hr Post Dose

3 Hr Post Dose

8 Hr Post Dose

FIGURE 24




FIGURE 24 - continued




FIGURE 25




FIGURE 26

Pools	clone ID	IVCD	Day 12 viability	Titer (g/L)	Day 0 image of Monoclonality
T4	2B6	1.54E+08	71.0	2.7	ok
	4C4	1.42E+08	60.5	2.6	ok
	4H8	1.18E+08	73.0	2.6	ok
	3C7	1.27E+08	72.5	2.1	ok
	4A3	1.35E+08	58.0	2.1	ok
	4B10	1.02E+08	66.0	2.1	ok
	3B4	1.07E+08	24.0	1.9	ok
	3F5	8.81E+07	49.5	1.8	ok
	2C7	1.27E+08	68.5	1.8	ok
	1C7	8.10E+07	82.0	1.7	ok
	3E10	9.36E+07	33.5	1.6	ok
	1F6	7.55E+07	72.0	1.6	ok
	4F1	1.28E+08	67.0	1.6	ok
	2F2	1.53E+08	55.5	1.6	ok
	2D8	9.63E+07	64.0	1.5	ok
	1C6	1.31E+08	33.0	1.5	ok
	4E4	1.20E+08	61.5	1.5	ok
	1D2	1.27E+08	62.5	1.4	ok
	4D7	1.14E+08	62.5	1.0	ok
T3	4B10	7.88E+07	54.0	2.5	ok
	2F12	7.65E+07	60.0	2.3	ok
	2H7	1.06E+08	66.5	2.3	ok
	2D3	1.09E+08	58.5	2.1	ok
	4D2	1.17E+08	59.5	2.1	ok
	1D3	6.12E+07	66.0	2.0	ok
	3G4	7.83E+07	63.5	2.0	ok
	3H9	9.84E+07	54.0	1.9	ok
	1G5	1.18E+08	70.5	1.9	ok
	2H3	8.87E+07	62.5	1.8	ok
	3D3	7.63E+07	61.5	1.8	ok
	2G3	9.55E+07	82.0	1.7	ok
	2F3	6.78E+07	59.0	1.7	ok
	3E9	1.07E+08	64.0	1.6	ok
	1F8	6.75E+07	68.0	1.2	ok
	1D11	9.41E+07	46.0	0.8	ok

FIGURE 27

Clone name	T4-2B6	T4-4H8	T4-3C7	T4-1C7	T4-1F6	T3-2H7	T3-1F8	T3-1G5	T3-1D3	T3-2G3
High Mannose	5.1	5.5	5.9	4.2	5	4.1	4.8	4.8	6.4	5.1
Sialylation	36	37.7	34.7	38.9	38.5	17	15.8	17.5	22.7	22.3
Galactosylation	35.2	35.4	35.1	32.5	32.4	51	32.3	50.2	45.7	47.5
Afucosylation	5.9	5.4	5.4	4.1	4.7	5.9	4.2	6	4.8	5.7
G0-N	0.5	0.4	0.5	0.3	0.4	0.4	0.5	0.4	0.3	0.4
G0F-N	1.1	1.1	1.2	1	1.1	0.8	2.3	1.2	1	1.1
G0	1.8	1.4	1.3	1	1.3	1.8	1.3	1.6	0.9	1.2
G0F	17.9	16.4	16.7	19	18.1	23.9	40.6	23.6	20.7	20.8
Man5	2.9	3	3.7	2.3	2.8	3.2	3.7	3.2	4.3	3.2
G1	2	2.4	2.2	1.6	2	2	1.3	2.6	2.3	3
G1'	0.4	0.3	0.3	0.2	0.3	0.5	0.2	0.4	0.3	0.4
G1F	17.2	17.5	17	16.4	15.7	26.9	16.5	26	24.1	24.3
G1F'	5.9	5.9	5.7	5.8	5.7	9.1	7.1	8.9	7.8	8.3
Man6	1.2	1.4	1.3	1.1	1.2	0.9	0.9	1.2	1.3	1.5
G1S1	1.2	0.9	1.1	1	0.7	1.2	0.9	1	1	0.7
G2F	9.7	9.3	9.9	8.5	8.7	12.5	7.2	12.3	11.2	11.5
Man7-1	0.5	0.4	0.4	0.3	0.4	ND	ND	ND	0.3	ND
Man7-2	0.5	0.7	0.5	0.5	0.6	ND	0.2	0.4	0.5	0.4
G2FS1	14.6	14	13.3	14.1	13.3	7.4	6.1	7.5	9	8.1
G2FS2	13	16.4	12.7	15.2	16	5.4	5.1	6.1	8.7	9.5
G3FS1	3	2.5	2.8	3.5	3.7	1.5	2	1.3	2.1	2.1
G3FS2	2.4	2.2	2.6	2.7	2.5	0.9	1.1	1	1.2	1.1
G3FS3	1.8	1.7	2.2	2.4	2.3	0.6	0.6	0.6	0.7	0.8

FIGURE 28A

Antibody acid sequences																																																							
	Clone #	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	
Clone #	1	M	S	Q	M	A	G	Q	C	P	Q	N	K	Y	F	D	S	L	L	H	A	C	I	P	C	Q	L	R	C	S	S	D	T	P	P	L	A	C	Q	R	Y	C	S	A	S	V	T	N	S	V	K	G	T	S	A
Clone #	2	V	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	L	H	A	C	I	P	C	Q	L	R	C	S	S	N	T	P	P	L	A	C	Q	R	Y	C	N	A	S	V	T	N	S	V	K	G	T	D	V
Clone #	3	M	L	R	M	A	G	Q	C	S	Q	N	E	Y	F	D	N	L	L	H	A	C	I	P	C	Q	L	R	C	S	S	N	T	P	P	L	A	C	Q	R	Y	C	N	T	S	V	T	N	S	V	K	G	T	N	A
Clone #	4	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	L	D	G	L	L	H	A	C	I	P	C	Q	L	R	C	S	S	N	T	P	P	L	A	C	Q	R	Y	C	N	A	S	A	T	D	S	V	K	G	T	N	A
Clone #	5	T	L	Q	V	A	G	Q	C	F	Q	N	E	Y	F	D	G	L	L	H	A	C	I	P	C	Q	L	R	C	S	S	N	A	P	L	T	C	R	Y	C	N	A	S	V	T	N	S	V	K	G	T	N	A		
Clone #	6	A	L	Q	M	A	G	Q	C	A	Q	N	E	Y	F	D	S	L	L	H	A	C	I	P	C	Q	L	R	C	S	S	N	T	P	P	L	T	C	R	Y	C	N	A	S	V	T	N	S	V	K	G	T	N	A	
Clone #	7	M	L	Q	M	A	E	Q	C	S	Q	N	E	Y	F	D	S	L	L	H	A	C	I	P	C	R	L	R	C	S	S	N	T	P	P	L	T	C	R	Y	C	N	A	S	V	T	N	S	V	K	G	T	N	A	
Clone #	8	V	L	Q	I	A	E	Q	C	P	Q	D	E	Y	F	D	S	L	L	H	A	C	I	P	C	Q	L	R	C	S	S	N	T	P	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	S	M	K	G	M	N	V
Clone #	9	M	L	Q	M	A	G	Q	C	S	Q	D	E	Y	F	D	G	L	L	H	A	C	I	P	C	Q	L	R	C	S	S	T	P	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	S	V	K	G	T	N	A	
Clone #	10	M	L	Q	M	A	G	Q	C	S	Q	D	E	Y	F	D	S	L	L	Y	A	C	M	P	C	Q	L	R	C	S	S	N	P	P	L	T	C	Q	R	Y	C	N	A	S	V	T	S	S	V	K	G	T	S	A	
Clone #	11	M	L	Q	M	A	E	R	C	S	Q	N	E	Y	F	D	S	L	L	Y	A	C	I	P	C	Q	L	R	C	S	S	N	T	P	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	S	V	K	G	T	N	A
Clone #	12	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	L	Y	A	C	I	P	C	Q	L	R	C	S	S	N	T	P	P	L	T	C	Q	R	Y	C	D	A	S	V	T	N	P	V	K	G	A	M	A

FIGURE 28C

Alphabet and Matrix		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52
Clone #	Matrix	42	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		43	V	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		44	V	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		45	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		46	V	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		47	V	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		48	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		49	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		50	V	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		51	T	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		52	V	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		53	T	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		54	T	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		55	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		56	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		57	V	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		58	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		59	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		60	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		61	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		62	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		63	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		64	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		65	T	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		66	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		67	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		68	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		69	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		70	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		71	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		72	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		73	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		
Clone #		74	M	L	Q	M	A	G	Q	C	S	Q	N	E	Y	F	D	S	L	H	A	E	I	P	C	Q	L	R	C	S	R	C	S	S	N	T	P	L	T	C	Q	R	Y	C	N	A	S	V	T	N	A		

FIGURE 29

SEQ ID NO:80 (Clone #71 + **Linker** + *human IgG1*)
MLQMAGQCSQNEYFDGLLYACIPCOLRCSSNTPPLACQRYCNASVTNSVKGTDA**GGGG**SPKSCDKTHTCPPCPAPELLGG
 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVISVLTVLHQDWLNGKEYKCK
 VSNKALPAPIEKTISKAKGQPREPQVYITLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNNYKTTTPVLDSDGSGFFLYSK
 LTVDKSRWQ^QQGNVFSQSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO:81 (Clone #72 + **Linker** + *human IgG1*)
MLQMAGQCSQNEYFDGLLYACIPCOLRCSSNTPPLACQRYCNASVTNSVKGTNA**GGGG**SPKSCDKTHTCPPCPAPELLGG
 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVISVLTVLHQDWLNGKEYKCK
 VSNKALPAPIEKTISKAKGQPREPQVYITLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNNYKTTTPVLDSDGSGFFLYSK
 LTVDKSRWQ^QQGNVFSQSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO:82 (Clone #74 + **Linker** + *human IgG1*)
MLQMAGQCPQDEYFDGLLYACIPCOLRCSSNTPPLACQRYCNASVTSSVKGTD**AGGGG**SPKSCDKTHTCPPCPAPELLGG
 PSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVISVLTVLHQDWLNGKEYKCK
 VSNKALPAPIEKTISKAKGQPREPQVYITLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNNYKTTTPVLDSDGSGFFLYSK
 LTVDKSRWQ^QQGNVFSQSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO:83 (Clone #75 + **Linker** + *human IgG1*)
MLPMAGQCPQNEYFDGLLYACIPCOLRCSSNTPPLACQRYCNASVTRSVEGTNA**GGGG**SPKSCDKTHTCPPCPAPELLGGP
 SVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVISVLTVLHQDWLNGKEYKCKV
 SNKALPAPIEKTISKAKGQPREPQVYITLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNNYKTTTPVLDSDGSGFFLYSKL
 TVDKSRWQ^QQGNVFSQSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO:84 (Clone #106 + **Linker** + *human IgG1*)
VSQTAGQCSQNEYFDGLLHACIPCOLRCSSDIPPLACQRYCNASVTNSVKGTNA**GGGG**SPKSCDKTHTCPPCPAPELLGGP
 SVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVISVLTVLHQDWLNGKEYKCKV
 SNKALPAPIEKTISKAKGQPREPQVYITLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNNYKTTTPVLDSDGSGFFLYSKL
 TVDKSRWQ^QQGNVFSQSVMHEALHNHYTQKSLSLSPGK

FIGURE 30

SEQ ID NO:1 (Extracellular domain of wild type human BCMA)
MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNAVSTNSVKGTNA

SEQ ID NO:85 (Extracellular domain of BAFF):
AVQGPEETVTQDCLQLIADSETPTIQKGSYTFVPWLLSFKRGSALEEKENKILVKETGYFFIYGQVLYTDKTYAMGHLL
QRKKVHVFGDELSLVTLCRCIQNMPEITLPNNSCYSAGIAKLEEGDELQLAIPRENAQISLDGDVVTFFGALKLL

SEQ ID NO:86 (Extracellular domain of APRIL):
AVLTQKQKKQHSVLLHVPINATSKDDSDVTEVMWQPALRRGRGLQAQGYGVRIQDAGVYLLYSQVLFQDVTFMTMG
QVVSRGQGRQETLFCIRSMPSHPDRAYNSCYSGVFFHLHQGDILSVIIPRARAKNLSPHGTFLGFVKL

SEQ ID NO:87 (a linker domain)
IEGRMD

SEQ ID NO:88 (a linker domain)
GGGS

FIGURE 31




FIGURE 32

